Diane Waku-Kouomou1, Mathew D Esona1, Elizabeth Pukuta2, Ionela Gouandijka-Vasilache3, Angeline Boula4, Benjamin A Dahl5, Vital Mondonge6, David Mekontso7, Gilbert Guifara8, Regis Mbary-Daba8, Jamie Lewis1, Ali Ahmed Yahaya9, Jason M Mwenda9, Kathleen F Cavallaro5, Jean Chrysostome Gody10, Jean-Jacques Muyembe2, Paul Koki-Ndombo4, Michael D Bowen1. 1. Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. 2. Institut National de Recherches Biomédicales, Kinshasa, Democratic Republic of the Congo. 3. Institut Pasteur de Bangui, Bangui, Central African Republic. 4. Mother and Child Center, Chantal Biya Foundation, Yaoundé, Cameroon. 5. Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, USA. 6. World Health Organization Country Office of Democratic Republic of the Congo, Kinshasa, Democratic Republic of the Congo. 7. World Health Organization Country Office of Cameroon, Yaoundé, Cameroon. 8. World Health Organization Country Office of Central African Republic, Bangui, Central African Republic. 9. World Health Organization Regional Office, Brazzaville, Republic of Congo. 10. Complexe Pédiatrique de Bangui, Bangui, Central African Republic.
Abstract
OBJECTIVES: The goal of the SURVAC pilot project was to strengthen disease surveillance and response in three countries; Cameroon (CAE), Democratic Republic of the Congo (DRC) and Central African Republic (CAR). METHODS: Seven laboratories involved in rotavirus surveillance were provided with equipment, reagents and supplies. CDC and WHO staff provided on-site classroom and bench training in biosafety, quality assurance, quality control (QC), rotavirus diagnosis using Enzyme Immunoassay (EIA) and genotyping of rotavirus strains using the Reverse Transcription Polymerase-chain reaction (RT-PCR). All laboratory data were reported through WHO/AFRO. RESULTS: Twenty-three staff members were trained on RT-PCR for rotavirus genotyping which was introduced for the first time in all three countries. In CAE, the number of samples analysed by EIA and RT-PCR increased tenfold between 2007 and 2013. In DRC, this number increased fivefold, from 2009 to 2013 whereas in CAR, it increased fourfold between 2011 and 2013. All laboratories passed WHO proficiency testing in 2014. CONCLUSION: Laboratory capacity was strengthened through equipping laboratories and strengthening a subregional laboratory workforce for surveillance of rotavirus gastroenteritis. Each of the three countries generated rotavirus surveillance and genotyping data enabling the mapping of circulating genotypes. These results will help monitor the impact of rotavirus vaccination in these countries.
OBJECTIVES: The goal of the SURVAC pilot project was to strengthen disease surveillance and response in three countries; Cameroon (CAE), Democratic Republic of the Congo (DRC) and Central African Republic (CAR). METHODS: Seven laboratories involved in rotavirus surveillance were provided with equipment, reagents and supplies. CDC and WHO staff provided on-site classroom and bench training in biosafety, quality assurance, quality control (QC), rotavirus diagnosis using Enzyme Immunoassay (EIA) and genotyping of rotavirus strains using the Reverse Transcription Polymerase-chain reaction (RT-PCR). All laboratory data were reported through WHO/AFRO. RESULTS: Twenty-three staff members were trained on RT-PCR for rotavirus genotyping which was introduced for the first time in all three countries. In CAE, the number of samples analysed by EIA and RT-PCR increased tenfold between 2007 and 2013. In DRC, this number increased fivefold, from 2009 to 2013 whereas in CAR, it increased fourfold between 2011 and 2013. All laboratories passed WHO proficiency testing in 2014. CONCLUSION: Laboratory capacity was strengthened through equipping laboratories and strengthening a subregional laboratory workforce for surveillance of rotavirus gastroenteritis. Each of the three countries generated rotavirus surveillance and genotyping data enabling the mapping of circulating genotypes. These results will help monitor the impact of rotavirus vaccination in these countries.
Authors: George A Alemnji; Songee Branch; Anton Best; Mireille Kalou; Bharat Parekh; Wanjiru Waruiru; Eric Milstrey; William Conn; John N Nkengasong; Shirley Lecher Journal: Glob Public Health Date: 2012-04-23
Authors: Cathy A Petti; Christopher R Polage; Thomas C Quinn; Allan R Ronald; Merle A Sande Journal: Clin Infect Dis Date: 2005-12-20 Impact factor: 9.079
Authors: Jason M Mwenda; Kinkela Mina Ntoto; Almaz Abebe; Christabel Enweronu-Laryea; Ismail Amina; Jackson Mchomvu; Annet Kisakye; Evans M Mpabalwani; Isoro Pazvakavambwa; George E Armah; L M Seheri; Nicholas M Kiulia; N Page; Marc-Alain Widdowson; A Duncan Steele Journal: J Infect Dis Date: 2010-09-01 Impact factor: 5.226
Authors: Mapaseka Seheri; Leah Nemarude; Ina Peenze; Lufuno Netshifhefhe; Martin M Nyaga; Harry G Ngobeni; Gugu Maphalala; Lorens L Maake; A Duncan Steele; Jason M Mwenda; Jeffrey M Mphahlele Journal: Pediatr Infect Dis J Date: 2014-01 Impact factor: 2.129
Authors: Gervais Ondobo Andze; Abel Namsenmo; Benoit Kebella Illunga; Ditu Kazambu; Dieula Delissaint; Christopher Kuaban; Francois-Xavier Mbopi-Kéou; Wilfred Gabsa; Leopold Mulumba; Jean Pierre Bangamingo; John Ngulefac; Melissa Dahlke; David Mukanga; Peter Nsubuga Journal: Pan Afr Med J Date: 2011-12-14
Authors: Elizabeth S Pukuta; Mathew D Esona; Adolphe Nkongolo; Mapaseka Seheri; Mingiele Makasi; Michel Nyembwe; Vital Mondonge; Benjamin A Dahl; M Jeffrey Mphahlele; Kathleen Cavallaro; Jon Gentsch; Michael D Bowen; Diane Waku-Kouomou; Jean-Jacques Muyembe Journal: Pediatr Infect Dis J Date: 2014-04 Impact factor: 3.806
Authors: Angeline Boula; Diane Waku-Kouomou; Mina Njiki Kinkela; Mathew D Esona; Grace Kemajou; David Mekontso; Mapaseka Seheri; Valantine Ngum Ndze; Irene Emah; Serge Ela; Benjamin A Dahl; Marie Kobela; Kathleen F Cavallaro; Georges Alain Etoundi Mballa; Jon R Genstch; Michael D Bowen; Paul Koki Ndombo Journal: Infect Genet Evol Date: 2014-09-16 Impact factor: 4.393
Authors: Virginie Banga-Mingo; Diane Waku-Kouomou; Jean Chrysostome Gody; Mathew D Esona; Jean Fandema Yetimbi; Regis Mbary-Daba; Benjamin A Dahl; Leon Dimanche; Thomas d'Aquin Koyazegbe; Vianney Tricou; Kathleen F Cavallaro; Gilbert Guifara; Michael D Bowen; Ionela Gouandjika-Vasilache Journal: Infect Genet Evol Date: 2014-09-02 Impact factor: 4.393
Authors: Christopher C Moore; Shevin T Jacob; Patrick Banura; Jixian Zhang; Suzanne Stroup; David R Boulware; W Michael Scheld; Eric R Houpt; Jie Liu Journal: Clin Infect Dis Date: 2019-01-07 Impact factor: 9.079
Authors: Ulrich Aymard Ekomi Moure; Virginie Banga-Mingo; Jean Chrysostom Gody; Jason M Mwenda; Jean Fandema; Diane Waku-Kouomou; Casimir Manengu; Thomas D'Aquin Koyazegbe; Mathew D Esona; Michael D Bowen; Ionela Gouandijka-Vasilache Journal: BMC Res Notes Date: 2018-01-05
Authors: Anna C Seale; Coll Hutchison; Silke Fernandes; Nicole Stoesser; Helen Kelly; Brett Lowe; Paul Turner; Kara Hanson; Clare I R Chandler; Catherine Goodman; Richard A Stabler; J Anthony G Scott Journal: Wellcome Open Res Date: 2017-09-26